Wilsie Larissa C, Orlando Robert A
Department of Biochemistry and Molecular Biology, Health Sciences Center, University of New Mexico, Albuquerque, NM 87131-0001, USA.
J Biol Chem. 2003 May 2;278(18):15758-64. doi: 10.1074/jbc.M208786200. Epub 2003 Feb 21.
It has been proposed that clearance of cholesterol-enriched very low density lipoprotein (VLDL) particles occurs through a multistep process beginning with their initial binding to cell-surface heparan sulfate proteoglycans (HSPG), followed by their uptake into cells by a receptor-mediated process that utilizes members of the low density lipoprotein receptor (LDLR) family, including the low density lipoprotein receptor-related protein (LRP). We have further explored the relationship between HSPG binding of VLDL and its subsequent internalization by focusing on the LRP pathway using a cell line deficient in LDLR. In this study, we show that LRP and HSPG are part of a co-immunoprecipitable complex at the cell surface demonstrating a novel association for these two cell surface receptors. Cell surface binding assays show that this complex can be disrupted by an LRP-specific ligand binding antagonist, which in turn leads to increased VLDL binding and degradation. The increase in VLDL binding results from an increase in the availability of HSPG sites as treatment with heparinase or competitors of glycosaminoglycan chain addition eliminated the augmented binding. From these results we propose a model whereby LRP regulates the availability of VLDL binding sites at the cell surface by complexing with HSPG. Once HSPG dissociates from LRP, it is then able to bind and internalize VLDL independent of LRP endocytic activity. We conclude that HSPG and LRP together participate in VLDL clearance by means of a synergistic relationship.
有人提出,富含胆固醇的极低密度脂蛋白(VLDL)颗粒的清除是一个多步骤过程,始于它们最初与细胞表面硫酸乙酰肝素蛋白聚糖(HSPG)结合,随后通过受体介导的过程被细胞摄取,该过程利用低密度脂蛋白受体(LDLR)家族的成员,包括低密度脂蛋白受体相关蛋白(LRP)。我们通过使用缺乏LDLR的细胞系,聚焦于LRP途径,进一步探讨了VLDL与HSPG结合及其随后内化之间的关系。在本研究中,我们表明LRP和HSPG是细胞表面共免疫沉淀复合物的一部分,证明了这两种细胞表面受体之间的新关联。细胞表面结合试验表明,这种复合物可被LRP特异性配体结合拮抗剂破坏,这反过来又导致VLDL结合和降解增加。VLDL结合增加是由于HSPG位点可用性增加,因为用肝素酶或糖胺聚糖链添加的竞争者处理消除了增强的结合。从这些结果中,我们提出了一个模型,即LRP通过与HSPG复合来调节细胞表面VLDL结合位点的可用性。一旦HSPG与LRP解离,它就能够独立于LRP内吞活性结合并内化VLDL。我们得出结论,HSPG和LRP通过协同关系共同参与VLDL清除。